Bile Acid Receptors As Targets for the Treatment of Dyslipidemia and Cardiovascular Disease

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2012 May 3

PMID 22550135

Citations 126

Authors

Geoffrey Porez

Janne Prawitt

Barbara Gross

Bart Staels

Affiliations

Soon will be listed here.

Abstract

Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and atherosclerosis. When dyslipidemia coincides with other metabolic disorders such as obesity, hypertension, and glucose intolerance, defined as the metabolic syndrome (MS), individuals present an elevated risk to develop type 2 diabetes (T2D) as well as CVD. Because the MS epidemic represents a growing public health problem worldwide, the development of therapies remains a major challenge. Alterations of bile acid pool regulation in T2D have revealed a link between bile acid and metabolic homeostasis. The bile acid receptors farnesoid X receptor (FXR) and TGR5 both regulate lipid, glucose, and energy metabolism, rendering them potential pharmacological targets for MS therapy. This review discusses the mechanisms of metabolic regulation by FXR and TGR5 and the utility relevance of natural and synthetic modulators of FXR and TGR5 activity, including bile acid sequestrants, in the treatment of the MS.

Citing Articles

Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.

Termite F, Archilei S, DAmbrosio F, Petrucci L, Viceconti N, Iaccarino R Antioxidants (Basel). 2025; 14(1).

PMID: 39857390 PMC: 11759774. DOI: 10.3390/antiox14010056.

Bile acids and incretins as modulators of obesity-associated atherosclerosis.

Kirsch A, Gindlhuber J, Zabini D, Osto E Front Cardiovasc Med. 2025; 11():1510148.

PMID: 39834741 PMC: 11743266. DOI: 10.3389/fcvm.2024.1510148.

Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases.

Usman I, Anwar A, Shukla S, Pathak P Cardiovasc Hematol Disord Drug Targets. 2024; 24(1):13-39.

PMID: 38879769 DOI: 10.2174/011871529X310857240607103028.

The changing metabolic landscape of bile acids - keys to metabolism and immune regulation.

Mohanty I, Allaband C, Mannochio-Russo H, Abiead Y, Hagey L, Knight R Nat Rev Gastroenterol Hepatol. 2024; 21(7):493-516.

PMID: 38575682 DOI: 10.1038/s41575-024-00914-3.

Changes in bile acid subtypes and improvements in lipid metabolism and atherosclerotic cardiovascular disease risk: the Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) trial.

Heianza Y, Xue Q, Rood J, Clish C, Bray G, Sacks F Am J Clin Nutr. 2024; 119(5):1293-1300.

PMID: 38428740 PMC: 11130658. DOI: 10.1016/j.ajcnut.2024.02.019.

References

Stayrook K, Bramlett K, Savkur R, Ficorilli J, Cook T, Christe M . Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2004; 146(3):984-91. DOI: 10.1210/en.2004-0965. View

Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A . Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun. 2007; 362(4):793-8. DOI: 10.1016/j.bbrc.2007.06.130. View

. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251(3):351-64. DOI: 10.1001/jama.1984.03340270029025. View

Setchell K, Lawson A, Tanida N, Sjovall J . General methods for the analysis of metabolic profiles of bile acids and related compounds in feces. J Lipid Res. 1983; 24(8):1085-100. View

Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R . Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem. 2004; 279(44):45685-92. DOI: 10.1074/jbc.M404255200. View

Moschetta A, L Bookout A, Mangelsdorf D . Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004; 10(12):1352-8. DOI: 10.1038/nm1138. View

Urizar N, Dowhan D, Moore D . The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem. 2000; 275(50):39313-7. DOI: 10.1074/jbc.M007998200. View

Del Bas J, Ricketts M, Vaque M, Sala E, Quesada H, Ardevol A . Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner. Mol Nutr Food Res. 2009; 53(7):805-14. PMC: 4142053. DOI: 10.1002/mnfr.200800364. View

Hu T, Chouinard M, Cox A, Sipes P, Marcelo M, Ficorilli J . Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem. 2006; 281(52):39831-8. DOI: 10.1074/jbc.M606779200. View

10.

Guo G, Santamarina-Fojo S, Akiyama T, Amar M, Paigen B, Brewer Jr B . Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta. 2006; 1761(12):1401-9. PMC: 1751860. DOI: 10.1016/j.bbalip.2006.09.018. View

11.

Rizzo G, Disante M, Mencarelli A, Renga B, Gioiello A, Pellicciari R . The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol. 2006; 70(4):1164-73. DOI: 10.1124/mol.106.023820. View

12.

Vassileva G, Hu W, Hoos L, Tetzloff G, Yang S, Liu L . Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol. 2010; 205(3):225-32. DOI: 10.1677/JOE-10-0009. View

13.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

14.

Nilsson L, Abrahamsson A, Sahlin S, Gustafsson U, Angelin B, Parini P . Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem Biophys Res Commun. 2007; 357(3):707-11. DOI: 10.1016/j.bbrc.2007.03.196. View

15.

Rask-Madsen C, King G . Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2006; 3(1):46-56. DOI: 10.1038/ncpendmet0366. View

16.

Kim I, Ahn S, Inagaki T, Choi M, Ito S, Guo G . Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007; 48(12):2664-72. DOI: 10.1194/jlr.M700330-JLR200. View

17.

Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann A . Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008; 51(6):1831-41. DOI: 10.1021/jm7015864. View

18.

Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M . A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11):9435-40. DOI: 10.1074/jbc.M209706200. View

19.

Beysen C, Murphy E, Deines K, Chan M, Tsang E, Glass A . Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2011; 55(2):432-42. DOI: 10.1007/s00125-011-2382-3. View

20.

Zhang Y, Yin L, Anderson J, Ma H, Gonzalez F, Willson T . Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem. 2009; 285(5):3035-43. PMC: 2823426. DOI: 10.1074/jbc.M109.083899. View